{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:13:52Z","timestamp":1787181232968,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.transproceed.2010.08.045","type":"journal-article","created":{"date-parts":[[2010,11,20]],"date-time":"2010-11-20T09:24:13Z","timestamp":1290245053000},"page":"3503-3506","source":"Crossref","is-referenced-by-count":32,"title":["Randomized Trial of Thymoglobulin Versus Alemtuzumab (with Lower Dose Maintenance Immunosuppression) Versus Daclizumab in Living Donor Renal Transplantation"],"prefix":"10.1016","volume":"42","author":[{"given":"G.","family":"Ciancio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Gaynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Kupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tueros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"G.W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2010.08.045_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation","volume":"338","author":"Vincenti","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2010.08.045_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00007890-199901270-00016","article-title":"Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.08.045_bib3","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00007890-200204150-00015","article-title":"Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients","volume":"73","author":"Ciancio","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.08.045_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","article-title":"Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplant","volume":"66","author":"Gaber","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.08.045_bib5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/01.TP.0000081042.67285.91","article-title":"A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients","volume":"76","author":"Goggins","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.08.045_bib6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/01.sla.0000137140.79206.d0","article-title":"Long-term immunosuppression, without maintenance prednisone, after kidney transplantation","volume":"240","author":"Matas","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.transproceed.2010.08.045_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1034\/j.1600-6143.2003.00120.x","article-title":"Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study","volume":"3","author":"Knechtle","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.08.045_bib8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.TP.0000128625.29654.EB","article-title":"The use of Campath-1H as induction therapy in renal transplantation: preliminary results","volume":"78","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.08.045_bib9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1600-6143.2005.00822.x","article-title":"Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years","volume":"5","author":"Watson","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.08.045_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-6143.2008.02492.x","article-title":"Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up","volume":"9","author":"Tan","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.08.045_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000101290.20629.DC","article-title":"A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.08.045_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/01.tp.0000165847.05787.08","article-title":"A randomized trial of three transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring","volume":"80","author":"Ciancio","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.08.045_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1399-0012.2007.00774.x","article-title":"A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow up","volume":"22","author":"Ciancio","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2010.08.045_bib14","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0090-4295(03)00760-X","article-title":"Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplant under current immunosuppressive protocols","volume":"62","author":"Chkhotua","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.transproceed.2010.08.045_bib15","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/01.tp.0000209825.91632.ea","article-title":"Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience","volume":"81","author":"Hardinger","year":"2006","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451001273X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451001273X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T19:01:34Z","timestamp":1544122894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113451001273X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S004113451001273X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2010.08.045","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}